Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

  • Clinical Articles
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Summary

The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ceberg CP, Persson A, Brun A, Huiskamp R, Fyhr AS, Persson BBR, Salford LG (1995) Performance of BSH in patients with astrocytoma grades III-IV — a basis for boron neutron capture therapy. J Neurosurg 83: 79–85

    PubMed  Google Scholar 

  2. Fairchild RG, Bond VP (1985) Current status of 10B-neutron capture therapy: enhancement of tumor dose via beam filtration and dose rate and the effects of these parameters on minimum boron content: a theoretical evaluation. Int J Radiat Oncol Biol Phys 11: 831–840

    PubMed  Google Scholar 

  3. Gabel D (1994) Present status and perspectives of boron neutron capture therapy. Radiother Oncol 30: 199–205

    PubMed  Google Scholar 

  4. Gabel D, Holstein H, Larsson B, Gille L, Ericson G, Sacker D, Som P, Fairchild RG (1987) Quantitative neutron capture radiography for studying the biodistribution of tumor-seeking boroncontaining compounds. Cancer Res 47: 5451–5456

    PubMed  Google Scholar 

  5. Gabel D, Moss RL (1992) Boron neutron capture therapy: toward clinical trials of glioma treatment. Plenum, New York

    Google Scholar 

  6. Gabel D, Sauerwein W (1995) Approaching clinical trials of boron neutron capture therapy in Europe. In: Kogelnik HD (ed) Progress in radiooncology V. Monduzzi, Bologna, pp 315–319

    Google Scholar 

  7. Haritz D, Gabel D, Huiskamp R (1994) Clinical phase-I-study of Na2B12H11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). Int J Radiat Oncol Biol Phys 28: 1175–1181

    PubMed  Google Scholar 

  8. Haselsberger K, Radner H, Pendl G (1994) Boron neutron capture therapy: boron biodistribution and pharmacokinetics of Na2B12H11SH in patients with glioblastoma. Cancer Res 54: 6318–6320

    PubMed  Google Scholar 

  9. Haselsberger K, Radner H, Gössler W, Schlagenhaufen C, Pendl G (1994) Subcellular boron-10 localization in glioblastoma for boron neutron capture therapy with Na2B12H11SH. J Neurosurg 81: 741–744

    PubMed  Google Scholar 

  10. Hatanaka H (1986) Boron neutron capture therapy for tumors. Nishimura, Niigata

    Google Scholar 

  11. Hatanaka H, Nakagawa Y (1994) Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28: 1061–1066

    PubMed  Google Scholar 

  12. Oda Y, Takagaki M, Zhang Z, Kikuchi H, Kobayashi T, Kanda K (1993) Clinical experience with BNCT for malignant brain tumors In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in neutron capture therapy. Plenum, New York, pp 689–693

    Google Scholar 

  13. Otersen B, Haritz D, Grochulla F, Bergmann M, Sierralta W, Gabel D (1996) Binding and distribution of Na2B12H11SH on cellular and subcellular level in tumor tissue of glioma patients in boron neutron capture therapy. J Neurooncol: in press

  14. Slatkin DN (1991) A history of boron neutron capture therapy of brain tumors: postulation of a brain radiation dose tolerance limit. Brain 114: 1609–1629

    PubMed  Google Scholar 

  15. Soloway AH, Hatanaka H, Davis MA (1967) Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem 10: 714–717

    PubMed  Google Scholar 

  16. Stragliotto G, Fankhauser H (1995) Biodistribution of boron sulfhydryl for boron neutron capture therapy in patients with intracranial tumors. Neurosurgery 36: 285–293

    PubMed  Google Scholar 

  17. Tamat SR, Moore DE, Allen BJ (1987) Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry. Anal Chem 59: 1261–1264

    Google Scholar 

  18. Watkins PW (1992) Present status of the three-dimensional treatment planning methodologies for the Petten BNCT facility. In: Gabel D, Moss R (eds) Boron neutron capture therapy. Toward clinical trials of glioma treatment. Plenum, New York, pp 101–109

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry, University of Bremen, Bremen

    D. Gabel M.D. & D. Preusse

  2. Neurosurgical Clinic, Zentralkrankenhaus St. Jürgenstrasse, Bremen, Federal Republic of Germany

    D. Haritz & F. Grochulla

  3. Neurosurgical Clinic, Karl-Franzens-Universität, Graz, Austria

    K. Haselsberger

  4. Service de Neurochirurgie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    H. Fankhauser

  5. Department of Radiophysics, Lund University Hospital, Lund, Sweden

    C. Ceberg

  6. Bonn, Federal Republic of Germany

    H. -D. Peters

  7. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Federal Republic of Germany

    U. Klotz

Authors
  1. D. Gabel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Preusse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Haritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Grochulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Haselsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Fankhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Ceberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. -D. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U. Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gabel, D., Preusse, D., Haritz, D. et al. Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture. Acta neurochir 139, 606–612 (1997). https://doi.org/10.1007/BF01411994

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01411994

Keywords

Search

Navigation